A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection

Ähnliche Einträge

• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study
  von: Jonathan Williams, et al.
  Veröffentlicht: (2025)
• Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants
  von: Alessandra Cipriano, et al.
  Veröffentlicht: (2024)
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study
  von: Rosa Chan, et al.
  Veröffentlicht: (2025)
• Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects
  von: Jingcheng Chen, et al.
  Veröffentlicht: (2024)
• Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults
  von: Greg Rigdon, et al.
  Veröffentlicht: (2024)